Orange Book product · Brand (NDA)
CHANTIX
VARENICLINE TARTRATE
At a glance
May 10, 2006
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 10, 2006
20 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
VARENICLINE TARTRATE
Strength
EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 021928
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2021TYRVAYABrand (NDA)
NDA 213978 · OYSTER POINT PHARMA
- 2026VARENICLINE TARTRATEGeneric (ANDA)
ANDA 218985 · UMEDICA
- 2025VARENICLINE TARTRATEGeneric (ANDA)
ANDA 218302 · MICRO LABS
- 2025VARENICLINE TARTRATEGeneric (ANDA)
ANDA 213268 · RHODES PHARMS
- 2025VARENICLINE TARTRATEGeneric (ANDA)
ANDA 212879 · VIWIT PHARM
- 2025VARENICLINE TARTRATEGeneric (ANDA)
ANDA 214595 · AUROBINDO PHARMA
- 2025VARENICLINE TARTRATEGeneric (ANDA)
ANDA 216615 · SHILPA
- 2024VARENICLINE TARTRATEGeneric (ANDA)
ANDA 215048 · MACLEODS PHARMS LTD
- 2024VARENICLINE TARTRATEGeneric (ANDA)
ANDA 219106 · REGCON HOLDINGS
- 2024VARENICLINE TARTRATEGeneric (ANDA)
ANDA 215931 · DR REDDYS
- 2024VARENICLINE TARTRATEGeneric (ANDA)
ANDA 217115 · PIRAMAL
- 2024VARENICLINE TARTRATEGeneric (ANDA)
ANDA 213019 · AJANTA PHARMA LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

